PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY

oleh: Seok-Goo Cho, Tae Min Kim, Michał Taszner, Tsai Yun Chen, Aafia Chaudhry, Melanie Ufkin, Amulya Uppala, Ayesha Sabir, Hesham Mohamed, Srikanth Ambati, Emmanuel Bachy